Protara Therapeutics, Inc. – NASDAQ:TARA
Founder-led company
Protara Therapeutics stock price today
$3.05
-2.46
-44.65%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Protara Therapeutics stock price monthly change
+133.47%
month
Protara Therapeutics stock price quarterly change
+133.47%
quarter
Protara Therapeutics stock price yearly change
+193.09%
year
Protara Therapeutics key metrics
Market Cap | 177.43M |
Enterprise value | 15.58M |
P/E | -0.49 |
EV/Sales | N/A |
EV/EBITDA | -0.23 |
Price/Sales | N/A |
Price/Book | 0.32 |
PEG ratio | -0.04 |
EPS | -3.74 |
Revenue | N/A |
EBITDA | -45.46M |
Income | -42.47M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeProtara Therapeutics stock price history
Protara Therapeutics stock forecast
Protara Therapeutics financial statements
| Jun 2023 | 0 | -11.29M | |
|---|---|---|---|
| Sep 2023 | 0 | -9.86M | |
| Dec 2023 | 1.20M | -10.22M | -846.11% |
| Mar 2024 | 0 | -11.09M |
| Dec 2023 | 1.20M | -10.22M | -846.11% |
|---|---|---|---|
| Mar 2024 | 0 | -11.09M | |
| Oct 2025 | 0 | -7.70M | |
| Dec 2025 | 0 | -7.82M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 95141000 | 9.91M | 10.42% |
|---|---|---|---|
| Sep 2023 | 88467000 | 11.51M | 13.01% |
| Dec 2023 | 78954000 | 10.63M | 13.47% |
| Mar 2024 | 68134000 | 9.72M | 14.28% |
| Jun 2023 | -9.40M | 22.35M | 0 |
|---|---|---|---|
| Sep 2023 | -6.56M | 6.37M | -27K |
| Dec 2023 | -8.7M | 14.51M | 4K |
| Mar 2024 | -10.37M | 23.1M | -76K |
Protara Therapeutics alternative data
| Aug 2023 | 25 |
|---|---|
| Sep 2023 | 25 |
| Oct 2023 | 25 |
| Nov 2023 | 25 |
| Dec 2023 | 25 |
| Jan 2024 | 25 |
| Feb 2024 | 25 |
| Mar 2024 | 26 |
| Apr 2024 | 26 |
| May 2024 | 26 |
| Jun 2024 | 26 |
| Jul 2024 | 26 |
Protara Therapeutics other data
52.69%
-5.14%
of TARA is owned by hedge funds
5.92M
-568.31K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 253185 |
| Insider | Compensation |
|---|---|
| Mr. Jesse Shefferman (1972) Co-Founder, Chief Executive Officer, Pres & Director | $1,260,000 |
| Mr. Blaine T. Davis (1974) Chief Financial Officer, Principal Financial & Accounting Officer and Sec. | $635,310 |
Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. (1981) Chief Scientific Operations Officer | $626,180 |
-
What's the price of Protara Therapeutics stock today?
One share of Protara Therapeutics stock can currently be purchased for approximately $3.05.
-
When is Protara Therapeutics's next earnings date?
Unfortunately, Protara Therapeutics's (TARA) next earnings date is currently unknown.
-
Does Protara Therapeutics pay dividends?
No, Protara Therapeutics does not pay dividends.
-
How much money does Protara Therapeutics make?
Protara Therapeutics has a market capitalization of 177.43M.
-
What is Protara Therapeutics's stock symbol?
Protara Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TARA".
-
What is Protara Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Protara Therapeutics?
Shares of Protara Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Protara Therapeutics's key executives?
Protara Therapeutics's management team includes the following people:
- Mr. Jesse Shefferman Co-Founder, Chief Executive Officer, Pres & Director(age: 53, pay: $1,260,000)
- Mr. Blaine T. Davis Chief Financial Officer, Principal Financial & Accounting Officer and Sec.(age: 51, pay: $635,310)
- Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. Chief Scientific Operations Officer(age: 44, pay: $626,180)
-
Is Protara Therapeutics founder-led company?
Yes, Protara Therapeutics is a company led by its founder Mr. Jesse Shefferman.
-
How many employees does Protara Therapeutics have?
As Jul 2024, Protara Therapeutics employs 26 workers.
-
When Protara Therapeutics went public?
Protara Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 22 Oct 2014.
-
What is Protara Therapeutics's official website?
The official website for Protara Therapeutics is protaratx.com.
-
Where are Protara Therapeutics's headquarters?
Protara Therapeutics is headquartered at 345 Park Avenue South, New York, NY.
-
How can i contact Protara Therapeutics?
Protara Therapeutics's mailing address is 345 Park Avenue South, New York, NY and company can be reached via phone at +64 6 844 0337.
Protara Therapeutics company profile:
Protara Therapeutics, Inc.
protaratx.comExchange:
NASDAQ
Full time employees:
26
Industry:
Biotechnology
Sector:
Healthcare
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
345 Park Avenue South
New York, NY 10010
New York, NY 10010
CIK: 0001359931
ISIN: US74365U1079
CUSIP: 74365U107
